|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-5-4
|
|
pubmed:abstractText |
Both sirolimus and cyclosporine are immunosuppressants used in a combined regimen after organ transplantation. When coadministered with the innovator formulation of cyclosporine, sirolimus blood levels increase 3.3-fold due to a pharmacokinetic interaction. We assessed this drug interaction for potential differences when the innovator formulation is replaced by a generic cyclosporine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0031-6970
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
361-6
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16547714-Adult,
pubmed-meshheading:16547714-Aged,
pubmed-meshheading:16547714-Analysis of Variance,
pubmed-meshheading:16547714-Animals,
pubmed-meshheading:16547714-Area Under Curve,
pubmed-meshheading:16547714-Chemistry, Pharmaceutical,
pubmed-meshheading:16547714-Cross-Over Studies,
pubmed-meshheading:16547714-Cyclosporine,
pubmed-meshheading:16547714-Dogs,
pubmed-meshheading:16547714-Drug Interactions,
pubmed-meshheading:16547714-Drug Prescriptions,
pubmed-meshheading:16547714-Drug Therapy, Combination,
pubmed-meshheading:16547714-Drugs, Generic,
pubmed-meshheading:16547714-Fasting,
pubmed-meshheading:16547714-Female,
pubmed-meshheading:16547714-Humans,
pubmed-meshheading:16547714-Immunosuppressive Agents,
pubmed-meshheading:16547714-Kidney Transplantation,
pubmed-meshheading:16547714-Male,
pubmed-meshheading:16547714-Middle Aged,
pubmed-meshheading:16547714-Sirolimus,
pubmed-meshheading:16547714-Therapeutic Equivalency,
pubmed-meshheading:16547714-Time Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.
|
|
pubmed:affiliation |
Novartis Pharmaceuticals, Building WSJ 103.426, 4002 Basel, Switzerland. john.kovarik@novartis.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial
|
